Keros Therapeutics, Inc. (KROS)
NASDAQ: KROS · Real-Time Price · USD
53.62
-0.39 (-0.72%)
Nov 19, 2024, 4:00 PM EST - Market closed
Keros Therapeutics Ratios and Metrics
Market cap in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| Current | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
| Nov '24 Nov 19, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
| Market Capitalization | 2,172 | 1,191 | 1,323 | 1,369 | 1,635 | - | |
| Market Cap Growth | 130.41% | -9.94% | -3.39% | -16.27% | - | - | |
| Enterprise Value | 1,661 | 918 | 1,084 | 1,149 | 1,502 | - | |
| Last Close Price | 53.62 | 39.76 | 48.02 | 58.51 | 70.54 | - | |
| PS Ratio | 3347.02 | 7888.64 | - | 68.11 | - | - | |
| PB Ratio | 3.95 | 3.59 | 4.77 | 5.63 | 6.25 | - | |
| P/TBV Ratio | 4.09 | 3.59 | 4.77 | 5.63 | 6.25 | - | |
| EV/Sales Ratio | 2550.86 | 6076.87 | - | 57.16 | - | - | |
| Debt / Equity Ratio | 0.04 | 0.04 | 0.05 | 0.00 | 0.00 | 12.59 | |
| Asset Turnover | 0.00 | 0.00 | - | 0.08 | - | 0.52 | |
| Quick Ratio | 18.36 | 13.63 | 16.91 | 20.96 | 37.04 | 1.77 | |
| Current Ratio | 19.03 | 14.25 | 17.27 | 21.23 | 37.27 | 1.99 | |
| Return on Equity (ROE) | -43.82% | -50.19% | -40.21% | -23.27% | -34.60% | -186.16% | |
| Return on Assets (ROA) | -28.17% | -31.39% | -25.53% | -13.43% | -20.80% | -34.41% | |
| Return on Capital (ROIC) | -29.58% | -33.33% | -26.82% | -13.90% | -21.65% | -58.26% | |
| Earnings Yield | -8.36% | -12.84% | -7.91% | -4.29% | -2.77% | - | |
| FCF Yield | -6.56% | -10.66% | -5.39% | -4.61% | -2.27% | - | |
| Buyback Yield / Dilution | -21.32% | -16.66% | -8.17% | -50.48% | -566.41% | 50.70% | |
| Total Shareholder Return | -21.32% | -16.66% | -8.17% | -50.48% | -566.41% | 50.70% | |
Source: S&P Capital IQ. Standard template.
Financial Sources.